drugset / Trial / NCT02468063

To Assess the Efficacy of Early Introduction of a Combination of Low Dose Vasopressin Analogue in Addition to Noradrenaline as a Vasopressor in Patients of Cirrhosis With Septic Shock

NCT02468063

RandomizedParallel-groupOpen-labelTreatment

Summary

The consecutive patients admitted to Intensive care unit of Hepatology department of ILBS and full filling all the eligibility criteria will be enrolled in 1:1 ration by the process of randomization.- The study is an open level study. The investigators will strictly follow the randomization table to give therapy as per the intervention arm. * Intervention:-the therapeutic intervention is vasopressor i.e. noradrenaline alone and terlipressin along with noradrenaline to maintain the MAP \>65mm Hg. * Intervention arm * Arm (A) - Noradrenaline * Arm (B) - Noradrenaline + low dose terlipressin

Timeline

Start
2015-05-01
Primary completion
2017-05-31
Completion
2017-05-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Noradrenaline Unknown 3.75 ug
Comparator Noradrenaline Unknown 7.5 ug
Comparator Noradrenaline Unknown 30 ug
Comparator Noradrenaline Unknown 60 ug
Subject Terlipressin Peptide 2 mg

Indications